Related Experiment Video
Updated: Aug 14, 2026
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
Published on: July 28, 2010
[Expression of dihydropyrimidine dehydrogenase in human colorectal carcinoma and its clinical implications]
Ju-xiang Xiao1, Mei Han, Li Li
1Department of Medical Oncology, First Hospital of Xi'an Jiaotong University, Xi'an 710061, China. xiao_juxiang@yahoo.com.cn
Objective:
The study was to explore the dihydropyrimidine dehydrogenase (DPD) expression level in human colorectal carcinoma and its clinical implications.
Methods:
Fifty-three patients with colorectal carcinoma were detected by immunohistochemical stain. These patients had undergone radical surgical treatment in the First Hospital of Xi'an Jiaotong University and had been followed up for 5 years after the operation. cases Twenty-two had received 5-fluorouracil-based adjuvant chemotherapy.
Results:
DPD expression was predominantly observed in the cytoplasm of the tumor cells, and also partly in the nucleus. The positive rate of DPD expression was 73.58% (39/53). DPD expression in patients with different histopathology was obviously different (P < 0.05). There was no significant correlation between the expression of DPD and the efficacy of chemotherapy. By Kaplan-Meier methods, the survival patients with of negative DPD expression was longer than those with positive DPD expression, and then five-year survival rates were 12.97% and 42.86%, respectively (P < 0.05). The prognosis of patients with positive DPD expression was significantly poorer outcome than that of patients with negative DPD expression.
Conclusion:
These findings suggest that DPD expression might be one of the important prognostic parameters for colorectal cancer patients.
